keyword
MENU ▼
Read by QxMD icon Read
search

deb-tace hcc

keyword
https://www.readbyqxmd.com/read/29739489/safety-and-efficacy-analysis-of-deb-tace-treatment-in-elderly-patients-with-hepatocellular-carcinoma-a-comparative-cohort-study
#1
Qing Yang, Xiaosheng Jin, Fangpeng Ye, Bingru Zheng, Xiangpang Xie, Ya Luo, Zhenjing Shi, Changsheng Shi
The aim of this study was to explore the difference of liver function change, safety profiles and efficacy of drug-eluting bead transarterial chemoembolization (DEBTACE) therapy between elderly and middle-aged hepatocellular carcinoma (HCC) patients. 91 HCC patients were enrolled in this prospective cohort study. They were treated by DEB-TACE therapy and divided into elderly group (age >= 65 years, n=30) and middle-aged group (age < 65 years, n=61), liver function, safety profiles and treatment response were recorded...
May 8, 2018: Oncology Research
https://www.readbyqxmd.com/read/29661601/corrigendum-to-evaluation-of-texture-analysis-parameter-for-response-prediction-in-patients-with-hepatocellular-carcinoma-undergoing-drug-eluting-bead-transarterial-chemoembolization-deb-tace-using-biphasic-contrast-enhanced-ct-image-data-correlation-with-liver
#2
Christopher Kloth, Wolfgang Maximilian Thaiss, Rainer Kärgel, Rainer Grimmer, Jan Fritz, Sorin Dumitru Ioanoviciu, Dominik Ketelsen, Konstantin Nikolaou, Marius Horger
No abstract text is available yet for this article.
April 13, 2018: Academic Radiology
https://www.readbyqxmd.com/read/29609903/transarterial-chemoembolization-tace-in-the-management-of-hepatocellular-carcinoma-results-of-a-french-national-survey-on-current-practices
#3
A Fohlen, J P Tasu, H Kobeiter, J M Bartoli, J P Pelage, B Guiu
PURPOSE: To report current practices of transarterial chemoembolization (TACE) by interventional radiologists (IR) for hepatocellular carcinoma (HCC) through a French national survey. MATERIALS AND METHODS: An electronic survey was sent by e-mail to 232 IRs performing TACE in 32 private or public centers. The survey included 66 items including indications for TACE, technical aspects of TACE, other locally available treatments for HCC, follow-up imaging and general aspects of interventional radiology practices...
March 30, 2018: Diagnostic and Interventional Imaging
https://www.readbyqxmd.com/read/29587773/callispheres-drug-eluting-beads-versus-lipiodol-transarterial-chemoembolization-in-the-treatment-of-hepatocellular-carcinoma-a-short-term-efficacy-and-safety-study
#4
Baolin Wu, Jun Zhou, Gonghao Ling, Dongyong Zhu, Qingyun Long
BACKGROUND: The present study aimed to evaluate the short-term efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres Beads loaded with doxorubicin (DOX) in the treatment of Chinese patients with hepatocellular carcinoma (HCC) compared to conventional TACE (cTACE). METHODS: A total of 54 patients with HCC treated by TACE from June 2016 to February 2017 were retrospectively analyzed. These included 24 cases in the DEB-TACE group and 30 cases in the cTACE group...
March 27, 2018: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29555570/reproducibility-of-mrecist-in-measurement-and-response-assessment-for-hepatocellular-carcinoma-treated-by-transarterial-chemoembolization
#5
Moon Hyung Choi, Ga Eun Park, Soon Nam Oh, Michael Yong Park, Sung Eun Rha, Young Joon Lee, Seung Eun Jung, Joon-Il Choi
RATIONALE AND OBJECTIVES: To evaluate the reproducibility of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) for hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) using multiphasic computed tomography. MATERIALS AND METHODS: The institutional review board approved this retrospective study. We evaluated 97 patients who underwent TACE (60 conventional TACE [cTACE] and 37 drug-eluting bead TACE [DEB-TACE]) for HCC from 2010 to 2014...
March 16, 2018: Academic Radiology
https://www.readbyqxmd.com/read/29484132/cryoablation-with-drug-loaded-bead-embolization-in-the-treatment-of-unresectable-hepatocellular-carcinoma-safety-and-efficacy-analysis
#6
Jian-Ying Zeng, Xiang-Hao Piao, Zhong-Yuan Zou, Qing-Feng Yang, Zi-Lin Qin, Ji-Bing Chen, Liang Zhou, Li-Zhi Niu, Jian-Guo Liu
This study aimed to explore the efficacy and safety of drug-eluting bead (DEB) embolization (DEB-TACE) when combined with cryoablation in the treatment of unresectable hepatocellular carcinoma (HCC). The study was a single-center randomized controlled trial comprised of 60 patients with HCC conducted between August 2015 and October 2017. The patients were randomly divided into two groups: DEB-TACE combined with cryoablation (DEB-TACE-Cryo group) or cryoablation alone (Cryo group). Inter-group differences in overall survival, progression-free survival, and adverse reactions were assessed...
January 26, 2018: Oncotarget
https://www.readbyqxmd.com/read/29399283/efficacy-of-intra-arterial-contrast-enhanced-ultrasonography-during-transarterial-chemoembolization-with-drug-eluting-beads-for-hepatocellular-carcinoma
#7
Kazue Shiozawa, Manabu Watanabe, Takashi Ikehara, Shuhei Yamamoto, Takashi Matsui, Yoshinori Saigusa, Yoshinori Igarashi, Iruru Maetani
AIM: To assess the usefulness of intra-arterial contrast-enhanced ultrasonography (IAUS) during transarterial chemoembolization (TACE) with drug-eluting beads (DEB) for hepatocellular carcinoma (HCC). METHODS: Thirty two patients with 39 HCC underwent DEB-TACE guided with IAUS, and examined by contrast-enhanced ultrasonography (CEUS) or dynamic CT after DEB-TACE were enrolled in this study. CEUS findings before DEB-TACE and IAUS findings were compared. Treatments judged to be complete and incomplete for lesions were appropriate and insufficient, respectively...
January 27, 2018: World Journal of Hepatology
https://www.readbyqxmd.com/read/29381102/transvascular-therapy-of-hepatocellular-carcinoma-hcc-status-and-developments
#8
Daniel Gnutzmann, Nikolas Kortes, Migle Sumkauskaite, Anne Schmitz, Karl-Heinz Weiss, Boris Radeleff
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Only 30-40% of patients diagnosed with HCC are candidates for curative treatment options. The remaining majority of patients undergo local, regional or systemic palliative therapies. Transvascular therapy of HCC takes advantage of the fact that hypervascularized HCCs receive their main perfusion from the hepatic artery. In this context transvascular therapy describes different therapies: bland embolization (transarterial embolization, TAE), cTACE (conventional transarterial chemoembolization), DEB-TACE (TACE with drug-eluting beads, DEB) and SIRT (selective internal radiation therapy, radioembolization)...
April 2018: Minimally Invasive Therapy & Allied Technologies: MITAT
https://www.readbyqxmd.com/read/29375202/drug-eluting-beads-transarterial-chemoembolization-for-hepatocellular-carcinoma-current-state-of-the-art
#9
REVIEW
Antonio Facciorusso
Transarterial chemoembolization (TACE) represents the current gold standard for hepatocellular carcinoma (HCC) patients in intermediate stage. Conventional TACE (cTACE) is performed with the injection of an emulsion of a chemotherapeutic drug with lipiodol into the artery feeding the tumoral nodules, followed by embolization of the same vessel to obtain a synergistic effect of drug cytotoxic activity and ischemia. Aim of this review is to summarize the main characteristics of drug-eluting beads (DEB)-TACE and the clinical results reported so far in the literature...
January 14, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29374736/efficacy-and-safety-of-drug-eluting-bead-tace-with-microspheres-150-%C3%AE-m-for-the-treatment-of-hepatocellular-carcinoma
#10
Tim Sattler, Christina Bredt, Stefanie Surwald, Christian Rust, Johannes Rieger, Tobias Jakobs
BACKGROUND/AIM: To retrospectively evaluate the efficacy and safety of drug eluting bead (DEB) transarterial chemoembolisation (TACE) with microspheres <150 μm for the treatment of hepatocellular carcinoma (HCC) with respect to overall survival, progression-free survival, tumor response and the peri-interventional toxicity. MATERIALS AND METHODS: In this retrospective, single-center study we analyzed 32 HCC-patients (BCLC A: 10 patients, BCLC B: 17 patients, BCLC C: 5 patients), who were treated with (DEB) <15 μm (DCBeadM1®) loaded with epirubicin between 2011 and 2015...
February 2018: Anticancer Research
https://www.readbyqxmd.com/read/29305365/rash-and-subcutaneous-fat-necrosis-after-deb-tace-with-doxorubicin
#11
Ahmed Gamal Elsayed, James M Martin, Toni Pacioles
A 73-year-old woman with hepatocellular carcinoma localised to the liver was treated with doxorubicin-loaded drug-eluting beads through transcatheter arterial chemoembolisation (DEB-TACE). She developed subcutaneous, erythematous, tender nodules in her abdomen 3 days after the procedure. PET/CT scan that was done to evaluate for evidence of disease progression showed mild avidity of these nodules. Biopsy showed fatty necrosis. Nodules started to improve spontaneously 2 weeks after onset. At 8 weeks after onset, lesions stabilised in size and the associated tenderness and erythema resolved...
January 5, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29206595/assessment-of-response-to-transcatheter-arterial-chemoembolization-with-doxorubicin-eluting-microspheres-tumor-biology-and-hepatocellular-carcinoma-recurrence-in-a-5-year-transplant-cohort
#12
Tyler A Sandow, Stephen E Arndt, Abeer A Albar, Daniel A DeVun, David S Kirsch, Juan M Gimenez, Humberto E Bohorquez, Patrick J Gilbert, Paul T Thevenot, Kelley G Nunez, Gretchen A Galliano, Ari J Cohen, Dennis Kay, Paul M Gulotta
Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretransplantation model for posttransplantation recurrence risk. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective analysis, 93 consecutive patients (73 male, 20 female; mean age, 59.6 years; age range, 23-72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a 5-year period from July 7, 2011, to May 16, 2016...
March 2018: Radiology
https://www.readbyqxmd.com/read/29167967/safety-and-feasibility-of-chemoembolization-with-doxorubicin-loaded-small-calibrated-microspheres-in-patients-with-hepatocellular-carcinoma-results-of-the-miracle-i-prospective-multicenter-study
#13
Götz Richter, Boris Radeleff, Christian Stroszczynski, Philippe Pereira, Thomas Helmberger, Mark Barakat, Peter Huppert
PURPOSE: The MIRACLE I pilot study was designed as a preliminary investigation of safety and efficacy of Embozene TANDEM microspheres loaded with doxorubicin for treatment of locally untreatable (i.e., unresectable and not suitable for local thermal ablation) hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Patients with locally untreatable HCC (mono- or bilobar disease, ECOG performance status 0-2, Child-Pugh score < 11) were eligible for this single-arm multicenter study...
April 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29113030/recent-advances-in-transarterial-embolotherapies-in-the-treatment-of-hepatocellular-carcinoma
#14
REVIEW
Edward Wolfgang Lee, Sarah Khan
Management of hepatocellular carcinoma (HCC) can be maximized with the utilization of multiple treatment modalities including transplant, surgical resection and locoregional therapies including ablative therapies and transarterial embolotherapies. Although transplant and surgical resection offer the best clinical outcomes, a limited number of patients are amenable to these surgical treatment options due to the advanced disease at presentation. Transarterial embolotherapies including conventional transarterial chemoembolization (cTACE), bland transarterial embolization (TAE), drug-eluting beads transarterial chemoembolization (DEB-TACE) and selective internal radiation therapy (SIRT) with Yttrium 90 (90Y) have played an increasingly important role for these patients with unresectable HCC...
December 2017: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/29098752/hemobilia-immediately-after-transcatheter-arterial-chemoembolization-using-drug-eluting-beads-for-hepatocellular-carcinoma-with-intrahepatic-bile-duct-invasion
#15
Maiko Nishi, Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Transcatheter arterial chemoembolization (TACE) is used as a palliative treatment for unresectable hepatocellular carcinoma (HCC) worldwide. Recently, a novel drug delivery-embolic agent, the drug-eluting bead (DEB), was introduced for TACE. There are a few reports of tumor hemorrhage after TACE using DEB (DEB-TACE) for HCC. However, there have not been any reports of hemobilia immediately after DEB-TACE for HCC with intrahepatic bile duct invasion. Here, the first such case is reported. A 71-year-old woman was admitted to our hospital to undergo DEB-TACE for multiple HCCs with worsening left intrahepatic bile duct dilatation...
March 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/29097347/dual-balloon-infusion-microcatheter-for-selective-drug-eluting-bead-transarterial-chemoembolization-initial-feasibility-study
#16
Wayne L Monsky, Siddharth A Padia, Andrew Hal Hardy
PURPOSE: We aimed to demonstrate feasibility of the use of a dual-balloon infusion microcatheter for segmental/subsegmental drug-eluting bead transarterial chemoembolization (DEB-TACE). METHODS: Over a 16-month period, 15 segmental and 21 subsegmental DEB-TACE procedures were attempted using a dual-balloon anti-reflux microcatheter (IsoFlow™ microcatheter, Vascular Designs Inc.) in 21 patients (15 males; median age, 61 years; range, 49-82 years) with hepatocellular carcinoma (Barcelona clinic liver cancer stage A [n=4]; B [n=12]; C [n=5]) with one to three tumors, median size of 3...
November 2017: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/29090102/complete-remission-after-sequential-therapy-of-drug-eluting-beads-transarterial-chemoembolization-and-liver-resection-in-large-solitary-nodule-hepatocellular-carcinoma
#17
Juferdy Kurniawan, Andri Sanityoso Sulaiman, Sahat Basana Romanti Ezer Matondang, Toar Jean Maurice Lalisang, Ening Krisnuhoni, Steven Zulkifly
Hepatocellular carcinoma (HCC) is the fifth most prevalent and the second highest cause of death among cancer. The treatment of large solitary nodule HCC is still challenging. Transarterial chemoembolization (TACE) and liver resection are two modalities of therapy in HCC management. However, recurrence rate from each therapy is relatively high. We report a case of 46-year-old man diagnosed with large solitary nodule HCC, who was treated with drug eluting bead TACE (DEB-TACE) prior to liver resection. Studies about this combination are still limited and showed various results...
2017: Case Reports in Hepatology
https://www.readbyqxmd.com/read/29082223/healthcare-costs-of-transarterial-chemoembolization-in-the-treatment-of-hepatocellular-carcinoma
#18
Waleed Fateen, Farooq Khan, Richard J O'Neill, Martin W James, Stephen D Ryder, Guruprasad P Aithal
BACKGROUND: A meta-analysis comparing drug-eluting beads transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (cTACE) has recently been published. On balance, no significant differences were found in terms of objective response and overall survival. The impact on healthcare costs had been studied in small series based on a hypothetical model and was in favor of DEB-TACE. We aimed to evaluate and compare health-care costs and effectiveness of both modalities in a cohort of patients from Nottingham, UK...
2017: Journal of Hepatocellular Carcinoma
https://www.readbyqxmd.com/read/29063856/does-neoadjuvant-doxorubicin-drug-eluting-bead-transarterial-chemoembolization-improve-survival-in-patients-undergoing-liver-transplant-for-hepatocellular-carcinoma
#19
Dimitri Dorcaratto, Venkatesha Udupa, Niamh M Hogan, David P Brophy, Jeffrey W McCann, Donal Maguire, Justin Geoghegan, Colin P Cantwell, Emir Hoti
PURPOSE: We aimed to compare the overall (OS) and disease-free survival (DFS) of patients undergoing orthotopic liver transplant (OLT) for hepatocellular carcinoma who did and did not have neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization (DEB-TACE). METHODS: This is a retrospective study of 94 patients with HCC transplanted between 2000 and 2014 in a single tertiary center. Pre- and postoperative features, DFS and OS were compared between patients who received pre-OLT DEB-TACE (n=34, DEB-TACE group) and those who did not (n=60, non-TACE group)...
November 2017: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/28982886/parenchymal-liver-blood-volume-and-dynamic-volume-perfusion-ct-measurements-of-hepatocellular-carcinoma-in-patients-undergoing-transarterial-chemoembolization
#20
COMPARATIVE STUDY
Nils Rathmann, Kerim Kara, Johannes Budjan, Thomas Henzler, Arman Smakic, Stefan O Schoenberg, Steffen J Diehl
AIM: Prospective comparison of cone beam C-Arm CT based parenchymal liver blood volume (PLBV) and dynamic volume perfusion CT (dVPCT) measurements in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolisation (TACE) with drug-eluting beads (DEB). PATIENTS AND METHODS: In 16 patients, changes of PLBV and dVPCT measurements [arterial liver parenchyma (ALP); temporal maximum intensity projection (MIP); hepatic perfusion index (HPI); portal venous parenchyma] were correlated to one another and to the modified Response Evaluation Criteria in Solid Tumors (mRECIST)...
October 2017: Anticancer Research
keyword
keyword
109351
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"